Inaktiver Wert

Andere Sprachen CymaBay Therapeutics, Inc.

Aktien

A116DD

US23257D1037

CBAY

Verzögert Nasdaq Andere Börsenplätze 21:00:00 21.03.2024			% 5 Tage	% 1. Jan.
32,48 ^USD	+0,03 %		-.--%	+37,51 %

22.03.	Gilead Sciences schließt Übernahme von Cymabay für 4,3 Mrd. $ ab	MT
22.03.	CymaBay Therapeutics, Inc. kündigt Änderungen im Vorstand an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Gilead Sciences Announces Completion of Acquisition of CymaBay	25.03.
Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	22.03.
CymaBay Therapeutics : Acquisition/Asset Disposal - Form 8-K	22.03.
CymaBay Therapeutics, Inc. Announces Board Changes	22.03.
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	22.03.
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	22.03.
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	22.03.
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	22.03.
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	22.03.
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	15.03.
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	11.03.
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	04.03.
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	04.03.
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	04.03.
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update	28.02.
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.02.
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	21.02.
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20.02.
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY	16.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CymaBay Therapeutics, Inc.

Aktien

A116DD

US23257D1037

CBAY

Andere Sprachen

Filter